Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity
Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.
Monrol, which manufactures radiopharmaceuticals meeting high quality standards at its production facilities, plans to increase its current n.c.a. Lu-177 production capacity through the expansion of existing production lines at the Monrol Gebze facility in Turkey as well as the establishment of a new production facility at the Gebze campus. The expansion project will come into operation gradually and reach full capacity by 2026.
N.c.a. Lu-177 is the radionuclide that forms the basis of targeted radioligand therapy(*), widely used today in the treatment of prostate cancer and neuroendocrine tumors and expected to be used soon to treat other cancers as well.
“Prostate cancer is the most common type of cancer in men after lung cancer, with its incidence increasing rapidly around the world. By 2040, 2.3 million new cases of prostate cancer are predicted annually worldwide. The production capacity increase at our Gebze facility in Turkey, which will comply fully with EU and US quality standards, will meet the increasing global demand for n.c.a. Lu-177. In fact, we aim to make the Gebze production facility a “center of excellence” for the production of theranostic products,” commented Aydin Kucuk, General Manager of Monrol.
(*) Targeted radioligand therapy, is an innovative approach to cancer treatment. Multiple clinical trials are investigating the effects of this treatment approach on various types of cancers across the world.
ENDS
About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a. is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a. enables treatment options that have the potential today to improve treatment outcomes for certain cancer patients and may soon offer improved treatment options for others, thanks to ongoing clinical development. The unique properties of Lu-177 n.c.a. make it a desirable radioisotope for peptide receptor radionuclide therapy (PRRT) used to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. Monrol n.c.a. Lutetium-177 DMF has been listed by the FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911648623/en/
Contact information
For further information please contact:
Monrol
Aydın Küçük
General Manager
monrol@monrol.com
Media Enquiries
Alkim Aydın
Marketing Manager
alkim.aydin@monrol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Secures Largest Order in Company History with VoltaGrid Delivering Power Generation for One of the World’s Largest Data Centers21.10.2025 10:01:00 EEST | Press release
INNIO Group today announced the largest order by power delivery in its history: a groundbreaking 2.3 GW power infrastructure project featuring 92 power packs, each delivering 25 MW of output. The initiative with VoltaGrid strengthens INNIO’s position as a key energy solutions provider for the rapidly expanding U.S. data center sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021503080/en/ INNIO Secures Largest Order in Company History (c) INNIO “This landmark order underscores the strength of INNIO’s technology and our ability to power the AI revolution with smart, high-performance energy solutions,” said Dr. Olaf Berlien, President and CEO of INNIO Group. “We are proud to partner with VoltaGrid in shaping the energy infrastructure of tomorrow.” “This is a major step toward building the energy infrastructure for the AI era,” added Nathan Ough, CEO of VoltaGrid. “Together with INNIO, we’re delivering a scalable solut
P.I. Works Celebrates 20 Years of Shaping the Telecom Industry21.10.2025 10:00:00 EEST | Press release
P.I. Works, the leading independent provider of AI-driven mobile network automation, optimization, and assurance solutions, proudly celebrates its 20th anniversary. This milestone marks two decades of driving telecom innovation and enabling mobile operators to deliver superior network performance, operational efficiency, and customer experience worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021105217/en/ P.I. Works Celebrates 20 Year Anniversary From Network Optimization to AI-Driven Automation Founded in 2005, as mobile data traffic surged with the rise of 3G, P.I. Works introduced intelligent solutions to help operators plan, manage, and optimize their networks more efficiently. Over the years, the company pioneered Self-Organizing Network (SON) capabilities, establishing the foundation for large-scale automation and giving operators the agility to manage increasingly complex networks. Leading Through the 5G
The Coca-Cola Company and Gutsche Family Investments Agree to Sell Controlling Interest in Coca-Cola Beverages Africa to Coca-Cola HBC AG21.10.2025 09:00:00 EEST | Press release
The Coca-Cola Company and Gutsche Family Investments have agreed to sell a 75% controlling interest in Coca-Cola Beverages Africa Pty. Ltd. to Coca-Cola HBC AG, the companies announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020939952/en/ CCBA is the largest Coca-Cola bottler in Africa. It operates in 14 countries on the continent and accounts for about 40% of all Coca-Cola product volume sold across Africa. Coca-Cola HBC is one of the largest Coca-Cola bottlers in the world, with operations in 29 countries across Europe and Africa, including Nigeria and Egypt. Coca-Cola will sell 41.52% out of its 66.52% stake in CCBA to Coca-Cola HBC, and Coca-Cola HBC is acquiring 33.48% of CCBA that is held by GFI. In total, the transaction values 100% of CCBA at an equity value of US$3.4 billion. The transactions are targeted to close by the end of 2026. Coca-Cola and Coca-Cola HBC have also agreed to a separate option
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation21.10.2025 09:00:00 EEST | Press release
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/ Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their resear
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer21.10.2025 08:17:00 EEST | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical trial (NCT05720130) at the European Society for Medical Oncology (ESMO) 2025 congress. The presentation featured the first clinical results of 212Pb-ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy in mCRPC. “We are very encouraged by the completion of the treatment period of our Phase 1 trial, which has demonstrated a favorable safety profile and compelling anti-tumor activity for 212Pb-ADVC001," said Anna Karmann, MD PhD, Chief Medical Officer of AdvanCell. “These results underscore the potential of our therapy to meaningfully impact patients’ lives and advance treatment options in metastatic prostate cancer. I want to sincerely thank the investigators, clinical teams, and most importantly the patients and their families, whose commitment has made this important milestone pos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom